Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424189 | 0.76 | PAX8 (0.34) | — | |
| SCHEMBL4724125 | 0.74 | — | — | |
| SCHEMBL15416056 | 0.68 | ELANE (0.33) | ELANEFSCN1 | |
| SCHEMBL12076534 | 0.67 | ELANE (0.35) | ELANEFSCN1 | |
| SCHEMBL4721725 | 0.65 | GBA1 (0.34) | — | |
| SCHEMBL4723514 | 0.65 | HCAR3 (0.36) | — | |
| SCHEMBL7828132 | 0.63 | ELANE (0.35) | ELANEFSCN1 | |
| SCHEMBL21592982 | 0.63 | ELANE (0.41) | ELANEFSCN1 | |
| SCHEMBL11474405 | 0.61 | NPC1 (0.40) | ELANEFSCN1 | |
| SCHEMBL4723837 | 0.60 | HTT (0.37) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8367661-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8202859-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101620-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1605752-B1 | Sulfonamides for the treatment of congestive heart failure, their compositions and uses. | CYTOKINETICS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110112154-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2011-05-12 | — | — | US | disclosed |
| US-7888373-B2 | Heterocyclic sulfonamides as modulators of cardiac sarcomeres | CYTOKINETICS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100069370-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | ELANE 3508/4885FSCN1 850/4885 |
| US-20100069370-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNT2, MYLK2 | ELANE 2243/4885FSCN1 388/4885 |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | ELANE 3508/4885FSCN1 850/4885 |
| US-20110112154-A1 | Compounds, compositions and methods | TNNI3, TNNT2, MYLK2 | ELANE 2243/4885FSCN1 388/4885 |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | ELANE 3508/4885FSCN1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.